Officials from SurModics Inc., a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, announce that its proprietary hydrophilic technology is being used on Medtronic’s U.S. Food and Drug Administration (FDA) approved Resolute Integrity Drug-Eluting Stent (DES) delivery system for the treatment of coronary artery disease (CAD).
“We are extremely pleased that our hydrophilic coating was selected for use on the delivery catheter of Medtronic’s Resolute Integrity DES delivery system. SurModics values the long-standing relationship with Medtronic and remains steadfast in complementing the deliverability of the Resolute Integrity DES through our advanced hydrophilic coating platforms,” says Gary Maharaj, president and CEO of SurModics.
Advanced deliverability to navigate, successfully, the challenging anatomical sites faced by today’s interventional cardiologist is one unique attribute of the Resolute Integrity DES system.
Latest from Today's Medical Developments
- GrindingHub Americas launches in 2027 in Cincinnati, Ohio
- Methods Machine Tools now offers the Nakamura-Tome NT-Flex
- Battelle awards $900,000 in STEM education grants to Ohio schools
- #55 Lunch + Learn Podcast with KINEXON
- Starrett and Gerstner offer limited edition, American made 1950s replica wooden machinist tool chests
- EMCO’s UNIVERSALTURN 50: The new benchmark in universal turning
- Archetype's Expertise for Equity accelerates early-stage innovation
- Stratasys expands its AM solutions with Tritone's cutting-edge technology
